Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 15/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 12/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20103395 | 0.86 | ALDH1A1 (0.47) | CDK9CCNT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL20182440 | 0.80 | S1PR1 (0.51) | CDK9CCNT1S1PR1S1PR5ALDH1A1 | |
| SCHEMBL20103515 | 0.80 | ESR2 (0.47) | CDK9CCNT1RORC | |
| SCHEMBL18866894 | 0.73 | CDK9 (0.50) | CDK9CCNT1RORC | |
| SCHEMBL23203494 | 0.72 | CDK9 (0.41) | CDK9CCNT1RORC | |
| SCHEMBL20103345 | 0.72 | CDK9 (0.49) | CDK9CCNT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21688373 | 0.71 | CDK9 (0.56) | CDK9CCNT1 | |
| SCHEMBL7709716 | 0.71 | ALDH1A1 (0.47) | CDK9CCNT1ALDH1A1 | |
| SCHEMBL20103466 | 0.71 | CDK9 (0.46) | CDK9CCNT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2521074 | 0.70 | CCNT1 (0.50) | CDK9CCNT1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR55 | CDK9 3507/4885CCNT1 1748/4885S1PR1 457/4885 |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR55 | CDK9 3507/4885CCNT1 1748/4885S1PR1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.